The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma

Narendra Bharathy, Noah E. Berlow, Eric Wang, Jinu Abraham, Teagan P. Settelmeyer, Jody E. Hooper, Matthew N. Svalina, Yoshihiro Ishikawa, Keith Zientek, Zia Bajwa, Martin W. Goros, Brian S. Hernandez, Johannes E. Wolff, Michelle A. Rudek, Linping Xu, Nicole M. Anders, Ranadip Pal, Alexandria P. Harrold, Angela M. Davies, Arya AshokDarnell Bushby, Maria Mancini, Christopher Noakes, Neal C. Goodwin, Peter Ordentlich, James Keck, Douglas S. Hawkins, Erin R. Rudzinski, Bishwanath Chatterjee, Hans Peter Bächinger, Frederic G. Barr, Jennifer Liddle, Benjamin A. Garcia, Atiya Mansoor, Theodore J. Perkins, Christopher R. Vakoc, Joel E. Michalek, Charles Keller

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical need for decades. A single oncogenic fusion gene is associated with treatment resistance and a 40 to 45% decrease in overall survival. We previously showed that expression of this PAX3:FOXO1 fusion oncogene in alveolar RMS (aRMS) mediates tolerance to chemotherapy and radiotherapy and that the class I-specific histone deacetylase (HDAC) inhibitor entinostat reduces PAX3:FOXO1 protein abundance. Here, we established the antitumor efficacy of entinostat with chemotherapy in various preclinical cell and mouse models and found that HDAC3 inhibition was the primary mechanism of entinostat-induced suppression of PAX3:FOXO1 abundance. HDAC3 inhibition by entinostat decreased the activity of the chromatin remodeling enzyme SMARCA4, which, in turn, derepressed the microRNA miR-27a. This reexpression of miR-27a led to PAX3:FOXO1 mRNA destabilization and chemotherapy sensitization in aRMS cells in culture and in vivo. Furthermore, a phase 1 clinical trial (ADVL1513) has shown that entinostat is tolerable in children with relapsed or refractory solid tumors and is planned for phase 1B cohort expansion or phase 2 clinical trials. Together, these results implicate an HDAC3-SMARCA4-miR-27a-PAX3:FOXO1 circuit as a driver of chemoresistant aRMS and suggest that targeting this pathway with entinostat may be therapeutically effective in patients.

Original languageEnglish (US)
Article numberaau7632
JournalScience signaling
Volume11
Issue number557
DOIs
StatePublished - Nov 20 2018

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma'. Together they form a unique fingerprint.

  • Cite this

    Bharathy, N., Berlow, N. E., Wang, E., Abraham, J., Settelmeyer, T. P., Hooper, J. E., Svalina, M. N., Ishikawa, Y., Zientek, K., Bajwa, Z., Goros, M. W., Hernandez, B. S., Wolff, J. E., Rudek, M. A., Xu, L., Anders, N. M., Pal, R., Harrold, A. P., Davies, A. M., ... Keller, C. (2018). The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Science signaling, 11(557), [aau7632]. https://doi.org/10.1126/scisignal.aau7632